BridgeBio Pharma Inc. (NASDAQ: BBIO) reported Q3 EPS of ($1.08), $0.29 worse than the analyst estimate of ($0.79). Revenue for the quarter came in at $4.09 million versus the consensus estimate of $3.62 million.

For earnings history and earnings-related data on BridgeBio Pharma Inc. (BBIO) click here.